BDRX News and Press, Biodexa Pharmaceuticals PLC-ADR From 09/12/25

2025-09-12 14:11:54 ET More on Biodexa Pharmaceuticals Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals Read the full article on Seeking Alp...

2025-09-12 08:43:45 ET More on Biodexa Pharmaceuticals Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals Read the full article on Seeking Alp...

September 12, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of ...

On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic Options By: Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / September 8, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a late clinical-stage biopharmaceutical company developing a pipelin...

July 31, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeli...

CARDIFF, UK / ACCESS Newswire / July 28, 2025 / Familial Adenomatous Polyposis (FAP) is an inherited condition that puts people at a much greater risk of developing colon cancer. If left untreated, there is a near 100% likelihood that the person will develop colon or rectum cancer. Despite the...

2025-07-15 16:49:34 ET More on Biodexa Pharmaceuticals Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals Read the full article on Seeking Alp...

July 15, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for ...

July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing...

Unity Bancorp Inc. (UNTY) is expected to report $1.16 for Q2 2025 Aeon Co. Ltd. ADR (AONNY) is expected to report for Q1 2026 Asante Gold Corp (ASGOF) is expected to report for Q1 2026 Evergreen Corporation (EVGR) is expected to report for quarter end 2025-05-31 null (EGRVF) is ex...